MOORESTOWN, N.J., Aug. 16, 2017 -- CareKinesis, a division of Tabula Rasa HealthCare (NASDAQ:TRHC), a medication risk management services and comprehensive PACE-focused pharmacy, is launching the first science-based total Medication Risk Score that will help clinicians pinpoint areas to improve medication quality and safety.
|
|||
The Medication Risk Score serves as a quick and easy way for clinicians to assess which participants are at highest risk for drug problems and require medication management attention. This scoring system was developed over the last five years by CareKinesis and Tabula Rasa HealthCare (TRHC) research and development staff. The measure uses a 0 to 50 scale to evaluate pharmacokinetic risks (related to drug absorption, distribution, metabolism, and excretion) and pharmacodynamics risks (related to mechanisms of action and drug effects). The Medication Risk Score was validated through data analysis for more than 800,000 individuals and is being used by TRHC in a large-scale CMS innovation model.
In addition to helping clinicians understand medication risks, the score also has been demonstrated to correlate directly with medical expenditures. Lower risk scores are therefore associated with lower expenditures. While conventional models assess risk through analysis of chronic disease and cost, the Medication Risk Score is based entirely on accumulative multi-drug risk, which is wholly actionable by a clinician. These identified actionable medication risks can be then remediated or mitigated by the PACE clinical team and CareKinesis pharmacist.
According to CareKinesis President, Orsula V. Knowlton, PharmD, MBA, “The Medication Risk Scoring system will help our collective teams to become even more engaged with the data, fostering an increase in medication safety.” CareKinesis aims to reduce participants’ risk scores over time, as gradual medication regimen changes are safest. “Our PACE clients want to keep their participants safely in the community, avoiding hospital and facility-based long-term care. These Medication Risk Scores are the measure to allow us to do just that and help reduce medical costs.” The Medication Risk Score launches for use in PACE on September 1, 2017.
PACE organizations nationwide rely on CareKinesis to improve medication safety and adherence and to reduce hospitalizations and recidivism. CareKinesis accomplishes this through prospective, geriatric-trained and board certified pharmacist medication management services in collaboration with PACE prescribers, a proprietary electronic medication platform that includes its Medication Risk Mitigation Matrix®, adherence packaging choices, and flexible medication access options.
About CareKinesis
CareKinesis partners with healthcare organizations to provide personalized medication therapy management and pharmacy services for high-risk populations. The results are enhanced medication-related outcomes and greater operational efficiency. The CareKinesis Medication Care Plan Support Center and Medication Adherence Packaging Pharmacy deliver individually customized medicine using unique robotic technology and a proprietary web-based electronic medication management and reporting platform, EireneRx®. It is the first, national PACE-specific pharmacy and the market leader. For more information, please visit www.carekinesis.com.
About Tabula Rasa HealthCare
Tabula Rasa HealthCare (TRHC) is a leader in providing patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations, lower healthcare costs and manage risk. Medication risk management is TRHC’s leading offering, and its cloud-based software applications, including EireneRx® and MedWise Advisor®, provide solutions for a range of payers, providers and other healthcare organizations. www.tabulsrasahealthcare.com.
Contact Dianne Semingson [email protected] T: 215-870-0829


Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims
Robinhood Expands Sports Event Contracts With Player Performance Wagers
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 



